Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

NCT04361552 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study abandoned due to drug billing issues

Conditions

Cerebrovascular Accident
Chronic Obstructive Pulmonary Disease
Chronic Renal Failure
Coronary Artery Disease
Diabetes Mellitus
Malignant Neoplasm
SARS Coronavirus 2 Infection

Interventions

OTHER: Best Practice
BIOLOGICAL: Tocilizumab

Sponsor

Emory University

Collaborators

[object Object]